Posts Tagged spasticity

[ARTICLE] Is two better than one? Muscle vibration plus robotic rehabilitation to improve upper limb spasticity and function: A pilot randomized controlled trial – Full Text

Abstract

Even though robotic rehabilitation is very useful to improve motor function, there is no conclusive evidence on its role in reducing post-stroke spasticity. Focal muscle vibration (MV) is instead very useful to reduce segmental spasticity, with a consequent positive effect on motor function. Therefore, it could be possible to strengthen the effects of robotic rehabilitation by coupling MV. To this end, we designed a pilot randomized controlled trial (Clinical Trial NCT03110718) that included twenty patients suffering from unilateral post-stroke upper limb spasticity. Patients underwent 40 daily sessions of Armeo-Power training (1 hour/session, 5 sessions/week, for 8 weeks) with or without spastic antagonist MV. They were randomized into two groups of 10 individuals, which received (group-A) or not (group-B) MV. The intensity of MV, represented by the peak acceleration (a-peak), was calculated by the formula (2πf)2A, where f is the frequency of MV and A is the amplitude. Modified Ashworth Scale (MAS), short intracortical inhibition (SICI), and Hmax/Mmax ratio (HMR) were the primary outcomes measured before and after (immediately and 4 weeks later) the end of the treatment. In all patients of group-A, we observed a greater reduction of MAS (p = 0.007, d = 0.6) and HMR (p<0.001, d = 0.7), and a more evident increase of SICI (p<0.001, d = 0.7) up to 4 weeks after the end of the treatment, as compared to group-B. Likewise, group-A showed a greater function outcome of upper limb (Functional Independence Measure p = 0.1, d = 0.7; Fugl-Meyer Assessment of the Upper Extremity p = 0.007, d = 0.4) up to 4 weeks after the end of the treatment. A significant correlation was found between the degree of MAS reduction and SICI increase in the agonist spastic muscles (p = 0.004). Our data show that this combined rehabilitative approach could be a promising option in improving upper limb spasticity and motor function. We could hypothesize that the greater rehabilitative outcome improvement may depend on a reshape of corticospinal plasticity induced by a sort of associative plasticity between Armeo-Power and MV.

Introduction

Spasticity is defined as a velocity-dependent increase in muscle tone due to the hyper-excitability of muscle stretch reflex [1]. Spasticity of the upper limb is a common condition following stroke and traumatic brain injury and needs to be assessed carefully because of the significant adverse effects on patient’s motor functions, autonomy, and quality of life [2].

Different pharmacological and non-pharmacological approaches are currently available for upper limb spasticity management, as physiotherapy (including magnetic stimulation, electromagnetic therapy, sensory-motor techniques, and functional electrical stimulation treatment) and robot-assisted therapy [34]. In this regard, several studies suggest robotic devices, including the Armeo® (a robotic exoskeleton for the rehabilitation of upper limbs), may help reducing spasticity by modifying spasticity-related synaptic processes at either the brain or spinal level [513], resulting in spasticity reduction in antagonist muscles through, e.g., a strengthening of spinal reciprocal inhibition mechanisms [11].

Growing research is proposing segmental muscle vibration (MV) as being a powerful tool for the treatment of focal spasticity in post-stroke patients [1415]. Mechanical devices deliver low-amplitude/high-frequency vibratory stimuli to specific muscles [1617], thus offering strong proprioceptive inputs by activating the neural pathway from muscle spindle annulospiral endings to Ia-fiber, dorsal column–medial lemniscal pathway, the ventral posterolateral nucleus of the thalamus (and other nuclei of the basal ganglia), up to the primary somatosensory area (postcentral gyrus and posterior paracentral lobule of the parietal lobe), and the primary motor cortex [1819]. At the cortical network level, proprioceptive inputs can alter the excitability of the corticospinal pathway by modulating intracortical inhibitory and facilitatory networks within primary sensory and motor cortex, and affecting the strength of sensory inputs to motor circuits [2022]. In particular, periods of focal MV delivered alone can modify sensorimotor organization within the primary motor cortex (i.e., can increase or decrease motor evoked potential—MEP—and short intracortical inhibition (SICI) magnitude in the vibrated muscles, while opposite changes occur in the neighboring muscles), thus reducing segmental hyper-excitability and spasticity [2022].

While focal MV is commonly used to reduce upper limb post-stroke spasticity, there is no conclusive evidence on the role of robotic rehabilitation in such a condition [1417,2327]. A strengthening of the effects of neurorobotics and MV on spasticity could be achieved by combining MV and neurorobotics. The rationale for combining Armeo-Power and MV to reduce spasticity could lie in the summation and amplification of their single modulatory effects on corticospinal excitability [28]. Specifically, it is hypothesizable that MV may strengthen the learning-dependent plasticity processes within sensory-motor areas that are in turn triggered by the intensive, repetitive, and task-oriented movement training offered by Armeo-Power [2930]. Such an amplification may depend on a sort of associative plasticity (i.e., the one generated by timely coupling two different synaptic inputs) between MV and Armeo-Power [3133].

To the best of our knowledge, this is the first attempt to investigate such approach. Indeed, a previous study combining MV with conventional physiotherapy used Armeo only as evaluating tool [14].

The aim of our study was to assess whether a combined protocol employing MV and Armeo-Power training, as compared to Armeo-Power alone, may improve upper limb spasticity and motor function in patients suffering from a hemispheric stroke in the chronic phase. To this end, we compared the clinical and electrophysiological after-effects of Armeo-Power with or without MV on upper limb spasticity. We also assessed the effects on upper limb motor function and muscle activation, disability burden, and mood, given that spasticity may have significant negative consequences on these outcomes. Further, it is important to evaluate mood, as it may negatively affect functional recovery [3436], increase mortality [37], and weaken the compliance of the patient to the rehabilitative training [3839].[…]

Continue —>  Is two better than one? Muscle vibration plus robotic rehabilitation to improve upper limb spasticity and function: A pilot randomized controlled trial

 

Fig 2. Combined rehabilitative approach. https://doi.org/10.1371/journal.pone.0185936.g002

Advertisements

, , , , , ,

Leave a comment

[WEB SITE] Spasticity – Stroke.org

Spasticity

Spasticity Awareness Week is April 17 – 21, 2017. Please join us in raising awareness about this condition that affects over 12 million people worldwide.

The National Stroke Association has partnered with a growing number of leading organizations to form the Spasticity Alliance. To commemorate Spasticity Awareness Week in 2017, the Spasticity Alliance has launched a Spanish version of its website. Both English and Spanish websites contain resources for individuals living with spasticity, family members, and caregivers who want to learn more about spasticity. The English website can be found at spasticityalliance.org; the Spanish website can be found at spanish.spasticityalliance.org.

The resources below contain information about the symptoms of spasticity, management techniques and treatments that help to ease the symptoms of spasticity. While there is no cure for this condition, there are many tactics that can help individuals living with spasticity resume their normal daily activities.

WHAT IS SPASTICITY?

After a stroke, damage to the brain can block messages between muscles and the brain causing arm and leg muscles to cramp or spasm (spasticity), kind of like a bad charley horse. This will limit your coordination and muscle movement. This post-stroke condition makes daily activities such as bathing, eating and dressing more difficult.

Spasticity can cause long periods of strong contractions in major muscle groups, causing painful muscle spasms. These spasms can produce:

  • A tight fist
  • Bent elbow
  • Arm pressed against the chest
  • Stiff knee
  • Pointed foot
  • Stiffness in the arms, fingers or legs

CAN SPASTICITY BE TREATED?

There are many strategies and treatments for spasticity to help you recover, return to work and regain function. In order to achieve the best results possible, a mixture of therapies and medications are often used to treat spasticity. Ask a healthcare professional about the best treatment plan for you. Some of the options include:

  • Braces. Putting a brace on an affected limb
  • Exercises. Range-of-motion exercises
  • Stretching. Gentle stretching of tighter muscles
  • Movement. Frequent repositioning of body parts
  • Medications. Medications are available to treat the effects of spasticity
  • ITB Therapy. A programmable, battery-powered medical device that stores and delivers medication to treat some of the symptoms of severe spasticity
  • Injections. Injections block the chemicals that make muscles tight
  • Surgery. Surgery on the muscles or tendons and joints may block pain and restore movement

TIPS TO LIVE WITH SPASTICITY

Managing spasticity with assistive devices, aids and home adaptations can help ensure your safety and reduce the risk of spasticity-related falls. Physical and occupational therapists will recommend the appropriate aid(s) as well as safety procedures, maintenance and proper fit. Some modifications in your home to improve safety include:

  • Ramps
  • Grab bars
  • Raised toilet seats
  • Shower or tub bench
  • Plastic adhesive strips on the bottom of the bathtub
  • Braces, canes, walkers and wheelchairs may help you move about freely as you gain strength.

Always follow rehabilitation therapists’ recommendations regarding limitations and safety needs.

Spasticity Resources:

  Spasticity Checklist

  Faces of Stroke and Spasticity

  Spasticity Animated Video       Spasticity Infographic

 

  Tweet to Beat Spasticity

  Mobility Brochure

 

ADDITIONAL RESOURCES

Source: Spasticity | Stroke.org

Leave a comment

[Abstract] The effect of functional stretching exercises on functional outcomes in spastic stroke patients: A randomized controlled clinical trial

Abstract

Background

Stroke is the biggest cause of disability in adults. Spasticity is a primary impairment of stroke with a highly variable prevalence. In the present research, we aimed to determine the impact of functional stretching exercises on functional outcomes in stroke patients.

Methods

Thirty stroke patients were randomized into two groups-Experimental group and control group for the purposes of the study. The subjects in the experimental group participated in a functional stretching training program at the rehabilitation center thrice a week for four weeks. The subjects in both groups were evaluated in 3 intervals, once at baseline, once at the end of the program, and once at 2 months following the program. Clinical assessments, such as measuring spasticity, were conducted using the Modified Modified Ashworth Scale (MMAS). Functional outcomes were also evaluated, using the Timed Up and Go (TUG) test, as well as the Timed 10-Meter Walk Test (WTT). Friedman test in SPSS version 22.0 was used to analysis the response variables with respect to each stage of evaluation. Spearman rank correlation was also used to measure correlation among clinical assessments and functional outcomes.

Results

The comparison between two groups showed significant differences only in the Modified Modified Ashworth Scale and Visual Analogue Scale (VAS) post treatment. The experimental group showed significant differences in the MMAS (p = 0.002), WTT (p < 0.001), and TUG (p < 0.001) scores. Nevertheless, the scores of the control group were not significantly different in different stages of evaluation.

Conclusion

The findings of the study suggest that using functional stretching exercises can improve functional outcomes in chronic spastic stroke patients.

Source: The effect of functional stretching exercises on functional outcomes in spastic stroke patients: A randomized controlled clinical trial – ScienceDirect

, , ,

Leave a comment

[Abstract] The effect of kinesiotaping on hand function in stroke patients: A pilot study

Abstract

Upper extremity motor impairment is one of the most prevalent problems following stroke. Considering the functional importance of the upper extremity in the daily life, the purpose of this study was to investigate the effect of kinesiotaping (KT) on hand function and spasticity in individuals following a stroke. Eight individuals who had experienced a stroke, with their age ranging from 47 to 66, participated in this pretest-posttest clinical study. An I- strip of tape was placed on the extensor muscles of the forearm. Primary outcome measures were the Modified Modified Ashwoth Scale, Box and Block test, and Nine Hole Peg test. At the immediate assessment, there were significant differences between two hand function tests scores. Secondary assessment was done after one week and the results showed significant differences between two hand function test scores. There was no significant change in flexor muscles spasticity after the intervention. This pilot study indicated that KT in the direction of the extensor muscles could result in better hand function in stroke patients.

Source: The effect of kinesiotaping on hand function in stroke patients: A pilot study – Journal of Bodywork and Movement Therapies

, , , , , , , ,

Leave a comment

[Abstract] Robot-assisted mirroring exercise as a physical therapy for hemiparesis rehabilitation

Abstract:

The paper suggests a therapeutic device for hemiparesis that combines robot-assisted rehabilitation and mirror therapy. The robot, which consists of a motor, a position sensor, and a torque sensor, is provided not only to the paralyzed wrist, but also to the unaffected wrist to induce a symmetric movement between the joints. As a user rotates his healthy wrist to the direction of either flexion or extension, the motor on the damaged side rotates and reflects the motion of the normal side to the symmetric angular position. To verify performance of the device, five stroke patients joined a clinical experiment to practice a 10-minute mirroring exercise. Subjects on Brunnstrom stage 3 had shown relatively high repulsive torques due to severe spasticity toward their neutral wrist positions with a maximum magnitude of 0.300kgfm, which was reduced to 0.161kgfm after the exercise. Subjects on stage 5 practiced active bilateral exercises using both wrists with a small repulsive torque of 0.052kgfm only at the extreme extensional angle. The range of motion of affected wrist increased as a result of decrease in spasticity. The therapeutic device not only guided a voluntary exercise to loose spasticity and increase ROM of affected wrist, but also helped distinguish patients with different Brunnstrom stages according to the size of repulsive torque and phase difference between the torque and the wrist position.

Source: Robot-assisted mirroring exercise as a physical therapy for hemiparesis rehabilitation – IEEE Conference Publication

, , , , , , , , ,

Leave a comment

[ARTICLE] A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity – Full Text

Abstract

Introduction Stroke is the most disabling neurological disorder and often causes spasticity. Transmucosal cannabinoids (tetrahydrocannabinol and cannabidiol (THC:CBD), Sativex) is currently available to treat spasticity-associated symptoms in patients with multiple sclerosis. Cannabinoids are being considered useful also in the treatment of pain, nausea and epilepsy, but may bear and increased risk for cardiovascular events. Spasticity is often assessed with subjective and clinical rating scales, which are unable to measure the increased excitability of the monosynaptic reflex, considered the hallmark of spasticity. The neurophysiological assessment of the stretch reflex provides a precise and objective method to measure spasticity. We propose a novel study to understand if Sativex could be useful in reducing spasticity in stroke survivors and investigating tolerability and safety by accurate cardiovascular monitoring.

Methods and analysis We will recruit 50 patients with spasticity following stroke to take THC:CBD in a double-blind placebo-controlled cross-over study. Spasticity will be assessed with a numeric rating scale for spasticity, the modified Ashworth scale and with the electromyographical recording of the stretch reflex. The cardiovascular risk will be assessed prior to inclusion. Blood pressure, heart rate, number of daily spasms, bladder function, sleep disruption and adverse events will be monitored throughout the study. A mixed-model analysis of variance will be used to compare the stretch reflex amplitude between the time points; semiquantitative measures will be compared using the Mann-Whitney test (THC:CBD vs placebo) and Wilcoxon test (baseline vs treatment).

Introduction

Stroke is one of the most disabling neurological disease and frequently determines important chronic consequences such as spasticity. Prevalence of poststroke spasticity ranges from 4% to 42.6%, with the prevalence of disabling spasticity ranging from 2% to 13%.1 Treatment of poststroke spasticity is based on rehabilitation, local injection of botulinum toxin (BoNT) in the affected muscles for focal spasticity and/or use of classic oral drugs such as tizanidine, baclofen, thiocolchicoside and benzodiazepines, which are not always effective and have a good number of possible side effects.

The transmucosal administration of delta-9-tetrahydrocannabinol and cannabidiol (THC and CBD at 1:1 ratio oromucosal spray, Sativex) is able to reduce spasticity acting on endocannabinoid receptors CB1and CB2. This novel drug has been licensed after an extensive clinical trial programme2–4 in adult patients with multiple sclerosis who have shown no significant benefit from other antispasmodic drugs. More than 45 000 patient/years of exposure since its approval in more than 15 EU countries support their antispasticity effectiveness and safety profile in this indication.5 Besides improving spasticity, cannabinoids can be beneficial in reducing pain, chemotherapy-induced nausea and vomiting; moreover, they contribute to reducing seizures and to lowering eye pressure in glaucoma.6Cannabinoids can also exert psychological effects by lowering anxiety levels and inducing sedation or euphoria. Marijuana, which is the main source of cannabinoids, is declared illegal in many countries mostly because of the risk of abuse, dependence and withdrawal syndrome, related to the effect of its high amounts of THC. Several reports support an increased ischaemic stroke risk related to relevant abuse of smoked marijuana7–17 as well as synthetic cannabinoids.18–20 Ischaemic stroke following cannabis involves more frequently basal ganglia and cerebellum where CB1 and CB2 receptors show a higher expression.13

The ‘French Association of the Regional Abuse and Dependence Monitoring Centres Working Group on Cannabis Complications’ warns about the increased cardiovascular risk related to the use of herbal cannabis, mostly consisting of acute coronary syndromes and peripheral arteriopathies, potentially leading to life-threatening conditions.21 The detrimental consequences of cannabinoids could be attributed to the increase in heart rate22 as well as arterial spasms also in the context of a reversible cerebral vasoconstriction syndrome,23 but also vasculitis, postural hypotension and cardioembolism.24

On the other side, some studies support a beneficial effect on stroke evolution of cannabinoid receptors stimulation. In fact, cannabinoid-mediated activation of CB1 and CB2 receptors reduces inflammation and neuronal injury in acute ischaemic stroke.25 Activation of CB2 receptors shows protective effects after ischaemic injury26 and inhibits atherosclerotic plaque progression.27 28

To our knowledge, no correlations have been reported between haemorrhagic stroke and cannabinoids intake. In our opinion, the modification of blood pressure is the most important cannabinoid effect that should be taken into account in patients with a previous haemorrhagic stroke or predisposed to intracranial bleeding. Cannabinoids are indeed capable of inducing blood pressure fluctuations in a specific triphasic pattern (low-high-low) potentially harmful if the patient is with bleeding risk.29Ischaemic disease is not included among THC:CBD oromucosal spray contraindications. However, considering that, to our knowledge, no study has been performed with THC:CBD oromucosal spray on post-stroke spasticity, we believe that a particular caution should be used in stroke patients.

The decision of which method of measure is considered as end point is a major issue in studies involving spasticity. The definition of spasticity provided by Lance is one of the most precise and reliable, focusing on the stretch reflex as the neurophysiological equivalent of spasticity.30 Probably because of technical complexity and required expertise, neurophysiological approaches are rarely adopted. Clinical rating scales such as the modified Ashworth scale (MAS)31 or subjective scores such as the numeric rating scale (NRS) for spasticity are being widely used.32 33 Recent evidence supports the idea that MAS and NRS are indeed useful to quickly rate spasticity in a clinical setting, however NRS provide a very variable and imprecise assessment of many symptoms related to spasticity, but where spasticity itself is probably only a common factor.34 The adoption of stretch reflex as the most appropriate neurophysiological measure of spasticity increases the specificity and reduces the variability of the end point and is particularly suitable for clinical trials.

Our proposal is therefore to assess the efficacy of THC:CBD oromucosal spray in patients with spasticity following stroke as add-on to first-line antispasticity medications with an experimental pilot randomised placebo-controlled cross-over clinical trial using the stretch reflex as primary outcome measure. Prior to inclusion in the study, we propose strict selection criteria in order to reduce the risk of relevant side effects. […]

Continue —>  A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity | BMJ Open

 

Graphical representation of the study protocol, particularly depicting the cross-over design and the time points. THC/CBD, tetrahydrocannabinol/cannabidiol.

, , , ,

Leave a comment

[REVIEW] INFLUENCE OF TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION ON SPASTICITY, BALANCE, AND WALKING SPEED IN STROKE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS – Full Text PDF

Objective: To evaluate the influence of transcutaneous electrical nerve stimulation in patients with stroke through a systematic review and meta-analysis.

Methods: PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases were searched systematically. Randomized controlled trials assessing the effect of transcutaneous electrical nerve stimulation vs placebo transcutaneous electrical nerve stimulation on stroke were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcome was modified Ashworth scale (MAS). Meta-analysis was performed using the random-effect model.

Results: Seven randomized controlled trials were included in the meta-analysis. Compared with placebo transcutaneous electrical nerve stimulation, transcutaneous electrical nerve stimulation supplementation significantly reduced MAS (standard mean difference (SMD) = –0.71; 95% confidence interval (95% CI) = –1.11 to –0.30; p =0.0006), improved static balance with open eyes (SMD = –1.26; 95% CI = –1.83
to –0.69; p<0.0001) and closed eyes (SMD = –1.74; 95% CI = –2.36 to –1.12; p < 0.00001), and increased walking speed (SMD = 0.44; 95% CI = 0.05 to 0.84; p = 0.03), but did not improve results on the Timed Up and Go Test (SMD = –0.60; 95% CI=–1.22 to 0.03; p = 0.06).

Conclusion: Transcutaneous electrical nerve stimulation is associated with significantly reduced spasticity, increased static balance and walking speed, but has no influence on dynamic balance.

Download Full Text PDF

 

, , , , ,

Leave a comment

[Abstract] Effect of Close Kinematic Chain Exercises on Upper Limb Spasticity in Hemiparetic Adult

Abstract

Background: As upper limb spasticity is the major hindrance in quality of life in hemiparesis, this project emphasizes on the effect of close kinematic chain exercises on upper limb spasticity. So, the present study was conducted to find out the effect combined effect of conventional exercises with close kinematic chain exercises on spasticity.

Method: Comparative study was conducted at Krishna College of Physiotherapy, Karad.20 subjects with age group between 40–60 years were taken. Participants of Group A (10) were treated with close kinematic chain exercises along with conventional treatment & GroupB(10)only with conventional treatment. Exclusion criteria of the study was: 1. Associated psychological disorder. 2. Perceptual disorders. 3. Any visual & auditory impairment. 4. Any orthopaedic disorder.

Results: Statistical analysis was done using paired, unpaired ”t’’test, Mann Whitney test and Friedman statistics. The results showed statistically significant reduction in spasticity in group A as compared to group B (p<0.001).

Conclusion: The study shows that close kinematic chain exercises helps in normalizing tone, reducing spasticity in upper extremity hemiparesis.

Source: Indian Journals

, , , , , , ,

Leave a comment

[ARTICLE] Dose-Dependent Effects of Abobotulinumtoxina (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study – Full Text

Abstract

Background

AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited.

Objective

To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS.

Design

Secondary analysis of a phase 3 study (NCT01313299).

Setting

Multicenter, international, double-blind, placebo-controlled clinical trial.

Participants

A total of 243 adults with ULS >6 months after stroke or traumatic brain injury, aged 52.8 (13.5) years and 64.3% male, randomized 1:1:1 to receive a single-injection cycle of placebo or abobotulinumtoxinA 500 U or 1000 U (total dose).

Methods

The overall effect of injected doses were assessed in the primary analysis, which showed improvement of angles of catch in finger, wrist, and elbow flexors and of active range of motion against these muscle groups. This secondary analysis was performed at each of the possible doses received by finger, wrist, and elbow flexors to establish possible dose effects.

Main Outcome Measures

Angle of arrest (XV1) and angle of catch (XV3) were assessed with the Tardieu scale, and active range of motion (XA).

Results

At each muscle group level (finger, wrist, and elbow flexors) improvements in all outcome measures assessed (XV1, XV3, XA) were observed. In each muscle group, increases in abobotulinumtoxinA dose were associated with greater improvements in XV3 and XA, suggesting a dose-dependent effect.

Conclusions

Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for health care professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints.

Introduction

Upper limb spasticity (ULS) is a common symptom after stroke and traumatic brain injury (TBI) and is associated with impaired self-care and additional burden of care [1-5]. Among several treatment strategies, guidelines recommend intramuscular botulinum toxin injections as a first-line treatment for adults with ULS [6-11].

Botulinum toxin type A (BoNT-A) injections may target upper extremity muscle groups from the shoulder, to decrease adductor and internal rotation tone, to the elbow, wrist, fingers, and thumb, to decrease flexor tone [12,13]. Specific muscle selection is based on the pattern of muscle overactivity, functional deficits, and patient goals [6]. These goals include increased passive and active range of motion, improved function (feeding and dressing), easier care (palmar and axillary hygiene), and reduction of pain [13].

Evidence-based information on optimal dosing for clinical use is relatively sparse. Dosing is not interchangeable between different BoNT-A products; therefore, improving our understanding of product-specific dosing will minimize confusion among injectors and improve the quality of patient care [13].

Among BoNT-A formulations, abobotulinumtoxinA (Dysport; Galderma Laboratories, LP, Fort Worth, TX) has been shown to decrease muscle tone (as measured by the Modified Ashworth Scale [MAS]) [13-17] and pain [18] and to facilitate goal attainment [19] in adults with ULS. A recent systematic review [13] of 12 randomized controlled trials (RCTs) in ULS concluded that abobotulinumtoxinA (total dose range, 500-1500 U) was generally well-tolerated, with “strong evidence” to support reduced muscle tone.

This paper presents the results of a secondary analysis from a recently published large international clinical trial, demonstrating improved active range of motion after abobotulinumtoxinA treatment in adults with hemiparesis and ULS >6 months after stroke or TBI [20]. This phase 3, randomized, double-blind, placebo-controlled study demonstrated that a total dose of either 500 U or 1000 U abobotulinumtoxinA injected in the upper extremity also resulted in decreased muscle tone and improvements in global physician-assessed clinical benefit compared with placebo.

Apart from a systematic measurement of active range of motion (XA) against finger, wrist, and elbow flexors, another unique aspect of the trial was the assessment of spasticity at the finger, wrist, and elbow flexor groups with the Tardieu scale (TS) [21,22]. The TS is a standardized evaluation used to assess the angle of arrest at slow speed (ie, passive range of motion, XV1) and the angle of catch at fast speed (XV3). The trial demonstrated improvements for finger, wrist, and elbow joints at week 4 in XV3 at both abobotulinumtoxinA doses and in XA at 1000 U; for the 500-U dose, improvements in XA were seen in the finger flexors. Both doses were associated with a favorable safety profile [20]. This analysis aims to provide a detailed description of improvements in spasticity and the active range of motion for individual muscle groups by dose and to provide information on muscle-specific dosing, which can be used in future recommendations for injectors.

Continue —> Dose-Dependent Effects of Abobotulinumtoxina (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study – ScienceDirect

 

Figure 1. Change from baseline of Tardieu scale parameters and of active range of motion week 4 postinjection in (A) extrinsic finger flexors, (B) wrist flexors, and (C) elbow flexors. Dose groups were as follows (lowest to highest dose): 500 U/non-PTMG, 500 U/PTMG, 1000 U/non-PTMG, and 1000 U/PTMG. Standard deviations and mean change from baseline values are detailed in Table 3. PTMG = primary targeted muscle group; XV1 = passive range of motion; XV3 = angle of catch at fast speed; XA = active range of motion.

, , , , , , ,

Leave a comment

[Abstract] Effects of mirror therapy combined with neuromuscular electrical stimulation on motor recovery of lower limbs and walking ability of patients with stroke: a randomized controlled study 

To investigate the effectiveness of mirror therapy combined with neuromuscular electrical stimulation in promoting motor recovery of the lower limbs and walking ability in patients suffering from foot drop after stroke.

Randomized controlled study.

Inpatient rehabilitation center of a teaching hospital.

Sixty-nine patients with foot drop.

Patients were randomly divided into three groups: control, mirror therapy, and mirror therapy + neuromuscular electrical stimulation. All groups received interventions for 0.5 hours/day and five days/week for four weeks.

10-Meter walk test, Brunnstrom stage of motor recovery of the lower limbs, Modified Ashworth Scale score of plantar flexor spasticity, and passive ankle joint dorsiflexion range of motion were assessed before and after the four-week period.

After four weeks of intervention, Brunnstrom stage (P = 0.04), 10-meter walk test (P < 0.05), and passive range of motion (P < 0.05) showed obvious improvements between patients in the mirror therapy and control groups. Patients in the mirror therapy + neuromuscular electrical stimulation group showed better results than those in the mirror therapy group in the 10-meter walk test (P < 0.05). There was no significant difference in spasticity between patients in the two intervention groups. However, compared with patients in the control group, patients in the mirror therapy + neuromuscular electrical stimulation group showed a significant decrease in spasticity (P < 0.001).

1. Brewer L, Horgan F, Hickey A, Stroke rehabilitation: recent advances and future therapies. QJM 2013; 106: 1125. Google Scholar CrossRef, Medline
2. Bethoux F, Rogers HL, Nolan KJ, The effects of peroneal nerve functional electrical stimulation versus ankle-foot orthosis in patients with chronic stroke: a randomized controlled trial. Neurorehabil Neural Repair 2014; 28: 688697. Google Scholar Link
3. O’Dell MW, Dunning K, Kluding P, Response and prediction of improvement in gait speed from functional electrical stimulation in persons with poststroke drop foot. PM R 2014; 6: 587601; quiz 601. Google Scholar CrossRef, Medline
4. Michielsen ME, Selles RW, van der Geest JN, Motor recovery and cortical reorganization after mirror therapy in chronic stroke patients: a phase II randomized controlled trial. Neurorehabil Neural Repair 2011; 25: 223233. Google Scholar Link
5. Samuelkamaleshkumar S, Reethajanetsureka S, Pauljebaraj P, Mirror therapy enhances motor performance in the paretic upper limb after stroke: a pilot randomized controlled trial. Arch Phys Med Rehabil 2014; 95: 20002005. Google Scholar CrossRef, Medline
6. Sousa Nanji L, Torres Cardoso A, Costa J, Analysis of the Cochrane review: interventions for improving upper limb function after stroke. Cochrane Database Syst Rev 2014; 11: CD010820; Acta Med Port 2015; 28: 551553. Google Scholar
7. Thieme H, Mehrholz J, Pohl M, Mirror therapy for improving motor function after stroke. Cochrane Database Syst Rev 2012; 3: CD008449. Google Scholar CrossRef
8. Stein C, Fritsch CG, Robinson C, Effects of electrical stimulation in spastic muscles after stroke: systematic review and meta-analysis of randomized controlled trials. Stroke 2015; 46: 21972205. Google Scholar CrossRef, Medline
9. Knutson JS, Fu MJ, Sheffler LR, Neuromuscular electrical stimulation for motor restoration in hemiplegia. Phys Med Rehabil Clin N Am 2015; 26: 729745. Google Scholar CrossRef, Medline
10. Sabut SK, Sikdar C, Kumar R, Functional electrical stimulation of dorsiflexor muscle: effects on dorsiflexor strength, plantarflexor spasticity, and motor recovery in stroke patients. NeuroRehabilitation 2011; 29: 393400. Google Scholar Medline
11. You G, Liang H, Yan T. Functional electrical stimulation early after stroke improves lower limb motor function and ability in activities of daily living. NeuroRehabilitation 2014; 35: 381389. Google Scholar Medline
12. Kojima K, Ikuno K, Morii Y, Feasibility study of a combined treatment of electromyography-triggered neuromuscular stimulation and mirror therapy in stroke patients: a randomized crossover trial. NeuroRehabilitation 2014; 34: 235244. Google Scholar Medline
13. Kim H, Lee G, Song C. Effect of functional electrical stimulation with mirror therapy on upper extremity motor function in poststroke patients. J Stroke Cerebrovasc Dis 2014; 23: 655661. Google Scholar CrossRef, Medline
14. Yun GJ, Chun MH, Park JY, The synergic effects of mirror therapy and neuromuscular electrical stimulation for hand function in stroke patients. Ann Rehabil Med 2011; 35: 316321. Google Scholar CrossRef, Medline
15. Lee D, Lee G, Jeong J. Mirror Therapy with Neuromuscular Electrical Stimulation for improving motor function of stroke survivors: a pilot randomized clinical study. Technol Health Care 2016; 24: 503511. Google Scholar CrossRef, Medline
16. Gregson JM, Leathley M, Moore AP, Reliability of the Tone Assessment Scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. Arch Phys Med Rehabil 1999; 80: 10131016. Google Scholar CrossRef, Medline
17. Mehrholz J, Wagner K, Rutte K, Predictive validity and responsiveness of the functional ambulation category in hemiparetic patients after stroke. Arch Phys Med Rehabil 2007; 88: 13141319. Google Scholar CrossRef, Medline
18. Lee HJ, Cho KH, Lee WH. The effects of body weight support treadmill training with power-assisted functional electrical stimulation on functional movement and gait in stroke patients. Am J Phys Med Rehabil 2013; 92: 10511059. Google Scholar CrossRef, Medline
19. Flansbjer UB, Holmback AM, Downham D, Reliability of gait performance tests in men and women with hemiparesis after stroke. J Rehabil Med 2005; 37: 7582. Google Scholar CrossRef, Medline
20. Sawner KA, LaVigne JM, Brunnstrom S. Brunnstrom’s movement therapy in hemiplegia: a neurophysiological approach. 2nd ed. Philadelphia, PA: Lippincott, 1992. Google Scholar
21. Cho KH, Lee JY, Lee KJ, Factors related to gait function in post-stroke patients. J Phys Ther Sci 2014; 26: 19411944. Google Scholar CrossRef, Medline
22. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206207. Google Scholar CrossRef, Medline
23. Jung IG, Yu IY, Kim SY, Reliability of ankle dorsiflexion passive range of motion measurements obtained using a hand-held goniometer and Biodex dynamometer in stroke patients. J Phys Ther Sci 2015; 27: 18991901. Google Scholar CrossRef, Medline
24. Bakhtiary AH, Fatemy E. Does electrical stimulation reduce spasticity after stroke? A randomized controlled study. Clin Rehabil 2008; 22: 418425. Google Scholar Link
25. Sütbeyaz S, Yavuzer G, Sezer N, Mirror therapy enhances lower-extremity motor recovery and motor functioning after stroke: a randomized controlled trial. Arch Phys Med Rehabil 2007; 88: 555559. Google Scholar CrossRef, Medline
26. Arya KN. Underlying neural mechanisms of mirror therapy: implications for motor rehabilitation in stroke. Neurol India 2016; 64: 3844. Google Scholar CrossRef, Medline
27. Guo F, Xu Q, Abo Salem HM, The neuronal correlates of mirror therapy: a functional magnetic resonance imaging study on mirror-induced visual illusions of ankle movements. Brain Res 2016; 1639: 186193. Google Scholar CrossRef, Medline
28. Gondin J, Brocca L, Bellinzona E, Neuromuscular electrical stimulation training induces atypical adaptations of the human skeletal muscle phenotype: a functional and proteomic analysis. J Appl Physiol 2011; 110: 433450. Google Scholar CrossRef, Medline
29. Jones S, Man WD, Gao W, Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev 2016; 10: CD009419. Google Scholar CrossRef
30. Shin HK, Cho SH, Jeon HS, Cortical effect and functional recovery by the electromyography-triggered neuromuscular stimulation in chronic stroke patients. Neurosci Lett 2008; 442: 174179. Google Scholar CrossRef, Medline
31. Sheffler LR, Chae J. Neuromuscular electrical stimulation in neurorehabilitation. Muscle Nerve 2007; 35: 562590. Google Scholar CrossRef, Medline
32. Weerdesteyn V, de Niet M, van Duijnhoven HJ, Falls in individuals with stroke. J Rehabil Res Dev 2008; 45: 11951213. Google Scholar CrossRef, Medline
33. Yavuzer G, Selles R, Sezer N, Mirror therapy improves hand function in subacute stroke: a randomized controlled trial. Arch Phys Med Rehabil 2008; 89: 393398. Google Scholar CrossRef, Medline
34. Alfieri V. Electrical treatment of spasticity. Reflex tonic activity in hemiplegic patients and selected specific electrostimulation. Scand J Rehabil Med 1982; 14: 177182. Google Scholar Medline
35. King TIII. The effect of neuromuscular electrical stimulation in reducing tone. Am J Occup Ther 1996; 50: 6264. Google Scholar CrossRef, Medline
36. Rushton DN. Functional electrical stimulation and rehabilitation—an hypothesis. Med Eng Phys 2003; 25: 7578. Google Scholar CrossRef, Medline
37. Touzalin-Chretien P, Dufour A. Motor cortex activation induced by a mirror: evidence from lateralized readiness potentials. J Neurophysiol 2008; 100: 1923. Google Scholar CrossRef, Medline

Source: Effects of mirror therapy combined with neuromuscular electrical stimulation on motor recovery of lower limbs and walking ability of patients with stroke: a randomized controlled studyClinical Rehabilitation – Qun Xu, Feng Guo, Hassan M Abo Salem, Hong Chen, Xiaolin Huang, 2017

, , , , , ,

Leave a comment

%d bloggers like this: